$183.25 1.85 (1.02%)
19:59 EDT MSFT Stock Quote Delayed 30 Minutes
Previous Close $183.25
Market Cap 1,407.95B
PE Ratio 123.82
Volume (Avg. Vol.) 42.15M
Day's Range 180.41 - 184.27
52-Week Range 119.01 - 190.70
Dividend & Yield 1.72 (0.94%)
MSFT Stock Predictions, Articles, and Microsoft News
- From InvestorPlace
- From the Web
Interestingly, when you consider that Microsoft’s net income in fiscal 2000 was $9.42 billion, it grew just 29.4% over the next 15 years while revenues rose 307.6%, suggesting Microsoft’s share price didn’t do much in the first decade of the new millennium because of poor margins, not overzealous investors.
Microsoft stock has multiple, positive catalysts over the short term and the long term. These catalysts will push the shares higher.
While it’s tempting to pile your money into high-flying investments, cash-rich companies are the best stocks to buy in unpredictable markets.
We have a chance to open a new position in one of our favorite stocks: Microsoft (NASDAQ:MSFT).
By Thomas Niel
Sure, valuation is not dirt cheap. But in terms of quality and low-risk, it may be worth the price. As market uncertainty remains, consider Microsoft stock a buy.
Young investors aggressively bought the stock market dip in March, and here are the 10 stocks they bought the most.
Several billionaire investors believe the markets are overvalued. Here are seven Dow Jones stocks to buy in this uncertain environment.
Microsoft stock is in good hands with Satya Nadella. It stands to benefit from the global recovery and it will benefit from the shutdown.
It's time to slow down a bit with Zoom and sell bear call spreads in ZM stock as the stay at home situation improves.
If investors want to win and keep winning in the current stock market, they need to make sure they're aware of the technochasm.
Microsoft, Baidu, Spirit Airlines, Penn National Gaming and Kohl's were our top stock trades for Tuesday. So, let's look at the charts.
These hot stocks crushed it this earnings season, and most of them are turning coronavirus disruption into powerful tailwinds. But not all of them will continue to be winners.
Stocks rallied to close the week, again showing resilience in the face of troubling economic data. An extension of the oil rebound and more positive reopening also provided some ballast to equities.
Facebook made a $400 million deal, while video games logged a record Q1 in sales. Here's what happened in the stock market today.
It may be time to continue selling in May, but not for these all-star earnings stocks to buy. Here's why each stands out from the crowd.
These tech stocks stand to benefit as their hot new laptop releases arrive just in time to meet the demand of working from home.
You can count on these 20 stocks to buy if you’re betting on America in the long term. Here's why each will stand the test of time.
Microsoft stock is a winner, and that has never been more clear than today, with the stock powering to new highs despite the coronavirus pandemic.
From Analyst Ratings
Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Neoleukin Therapeutics (NLTX – Research Report) today and set a price target of $20.00. The company’s shares closed last Thursday at $14.16, close to its 52-week high of $14.82. According to TipRanks.com, Lee is a 3-star analyst with an average return of 1.4% and a
From Analyst Ratings
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Neoleukin Therapeutics (NLTX – Research Report), with a price target of $22.00. The company’s shares closed last Wednesday at $12.50. According to TipRanks.com, Burns is a 5-star analyst with an average return of 32.5% and a 81.0% success rate. Burns
From Simply Wall St
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we’d be remiss not to mention that insider sales have<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nltx/neoleukin-therapeutics/news/how-much-are-neoleukin-therapeutics-inc-nasdaqnltx-insiders-spending-on-buying-shares-2/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader